Development and Evaluation of New Choleretic Agent

Abstract

Background: The aim of the research is the determination of pharmacological activity during the development of the optimal way of a new choleretic agent obtaining. The multicomponent herbal medicinal product under the code name Hexaphyte (herbal multicomponent dry extract) is developed. It contains the following species of medicine plant raw materials: Helichrysum arenarium L., Tanacetum vulgare L., Rosa sp., Urtica dioica L., Mentha piperita L., Glycyrrhiza glabra L. in the ratio of 6:2:2:2:1:1. Materials and Methods: Herbal tea was extracted three times with hot water at the temperature of 75-85ºС; water extracts were combined, filtered and dried. Hexaphyte was standardized by the content of phenolic compounds – sum of flavonoids in terms of luteolin standard and isosalipurposide standard. Phenolic compounds (flavonoids) are dominating substances (35-37%) in the obtained extract. The obtained multicomponent medicine under the code name Hexaphyte was administered per os in the experimental and therapeutic dose of 250 mg/kg to the laboratory animals having experimental induced damages of gallbladder and liver. Results: In Hexaphyte the content of the flavonoid sum (CFS) referred to luteolin standard at a wavelength of 350 nm was not less than 4%; CFS referred to isosalipurposide standard at a wavelength of 315 nm was not less than 15%. It was revealed in the results of the realized experiments that it has a choleretic effect superior in a number of indicators to the activity of the Allochol reference drug. The pharmacotherapeutic effect of Hexaphyte at experimental damages of gallbladder and liver is due to the presence of biologically active substances, mainly of phenolic nature. Conclusion: The obtained results of the research argue the feasibility of using the developed multicomponent medicine Hexaphyte containing biologically active substances of phenolic nature in the prevention and complex treatment of hepatobiliary system diseases.